Are NMDA antagonistic properties relevant for antiparkinsonianlike activity in rats?—Case of amantadine and memantine
Authors:
- 1 October 1994
- journal article
- research article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 7 (3) , 155-166
Abstract
Summary Amantadine (25, 50, 100 mg/kg), memantine (5, 10, 20 mg/kg) and MK-801 (0.05, 0.1, 0.2 mg/kg), all having NMDA channel blocking properties, were compared in three tests used for screening of antiparkinsonian agents in rats, namely: haloperidol-induced catalepsy, locomotor activity in monoamine depleted rats and rotation in rats with a unilateral substantia nigra lesion. Additionally, plasma levels of amantadine and memantine were assessed to gain an insight into the concentration ranges achieved at behaviorally active doses. Amantadine and (+)-MK-801 produced dosedependent inhibition of haloperidol-induced catalepsy while memantine was less efficacious producing clear-cut anticataleptic action at a dose of 10 mg/kg only but failing at 20 mg/kg due to myorelaxant activity. All agents attenuated sedation in monoamine depleted rats with amantadine being the least and MK-801 being the most effective. The same rank order of efficacy was seen in inducing ipsilateral rotations in rats after a substantia nigra lesion. On the basis of the present study and published data, it can be assumed that the doses of amantadine, memantine and MK-801 showing antiparkinsonian-like activity in animals result in plasma levels leading to NMDA antagonism. However, in the haloperidol-induced catalepsy test the efficacy of amantadine was higher than memantine, while the opposite was true for rotation and reserpine-induced sedation indicating pharmacodynamic differences between both agents.Keywords
This publication has 42 references indexed in Scilit:
- Amantadine increases striatal dopamine turnover in MPTP‐treated miceDrug Development Research, 1993
- Milacemide therapy for Parkinson's diseaseMovement Disorders, 1993
- Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's diseaseJournal of Neural Transmission, 1992
- The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine‐depleted rats and MPTP‐treated monkeysAnnals of Neurology, 1991
- N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's DiseaseArchives of Neurology, 1991
- Anticataleptic potencies of glutamate-antagonistsAmino Acids, 1991
- Amantadine sulphate in treating Parkinson's disease: Clinical effects, psychometric tests and serum concentrationsJournal of Neurology, 1989
- Amantadine in depression: Relationship between behavioural effects and plasma levelsEuropean Journal of Clinical Pharmacology, 1973
- The effect of amantadine on motor activity and catalepsy in ratsPsychopharmacology, 1972
- Anticataleptic actions of amantadine hydroehlorideNaunyn-Schmiedeberg's Archives of Pharmacology, 1970